Cancertain

Executive Summary

Cancertain is a UK-based diagnostics company leveraging cutting-edge technology to personalize cancer treatment selection. Founded in 2018, the company aims to reduce the number of ineffective drug rounds, minimize side effects, and improve patient quality of life and survival. Currently at the pre-clinical stage, Cancertain has not yet disclosed funding, partnerships, or published data. If successful, its platform could address a critical unmet need in oncology by enabling physicians to identify the optimal therapy for each patient earlier. However, the company's early stage and lack of validation present significant risks.

Upcoming Catalysts (preview)

• Q3 2026Pre-clinical proof-of-concept data release40% success
• Q4 2026Seed or Series A funding round50% success
• H1 2027Initial strategic partnership with a pharmaceutical company or cancer center35% success